These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
79 related articles for article (PubMed ID: 22421369)
1. Enhancement of the cytotoxic potential of the mixed EGFR and DNA-targeting 'combi-molecule' ZRBA1 against human solid tumour cells by a bis-quinazoline-based drug design approach. Al-Safadi S; Domarkas J; Han Y; Brahimi F; Jean-Claude BJ Anticancer Drugs; 2012 Jun; 23(5):483-93. PubMed ID: 22421369 [TBL] [Abstract][Full Text] [Related]
2. Interaction of ionizing radiation and ZRBA1, a mixed EGFR/DNA-targeting molecule. Heravi M; Rachid Z; Goudarzi A; Schlisser A; Jean-Claude BJ; Radzioch D; Muanza TM Anticancer Drugs; 2009 Sep; 20(8):659-67. PubMed ID: 19581798 [TBL] [Abstract][Full Text] [Related]
3. Mechanism of action of a novel "combi-triazene" engineered to possess a polar functional group on the alkylating moiety: evidence for enhancement of potency. Brahimi F; Rachid Z; McNamee JP; Alaoui-Jamali MA; Tari AM; Jean-Claude BJ Biochem Pharmacol; 2005 Aug; 70(4):511-9. PubMed ID: 15982640 [TBL] [Abstract][Full Text] [Related]
4. The combi-targeting concept: chemical dissection of the dual targeting properties of a series of "combi-triazenes". Rachid Z; Brahimi F; Katsoulas A; Teoh N; Jean-Claude BJ J Med Chem; 2003 Sep; 46(20):4313-21. PubMed ID: 13678409 [TBL] [Abstract][Full Text] [Related]
5. The combi-targeting concept: selective targeting of the epidermal growth factor receptor- and Her2-expressing cancer cells by the complex combi-molecule RB24. Banerjee R; Huang Y; McNamee JP; Todorova M; Jean-Claude BJ J Pharmacol Exp Ther; 2010 Jul; 334(1):9-20. PubMed ID: 20348204 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of epidermal growth factor receptor-mediated signaling by "Combi-triazene" BJ2000, a new probe for Combi-Targeting postulates. Brahimi F; Matheson SL; Dudouit F; McNamee JP; Tari AM; Jean-Claude BJ J Pharmacol Exp Ther; 2002 Oct; 303(1):238-46. PubMed ID: 12235257 [TBL] [Abstract][Full Text] [Related]
7. Novel nitrogen mustard-armed combi-molecules for the selective targeting of epidermal growth factor receptor overexperessing solid tumors: discovery of an unusual structure-activity relationship. Rachid Z; Brahimi F; Qiu Q; Williams C; Hartley JM; Hartley JA; Jean-Claude BJ J Med Chem; 2007 May; 50(11):2605-8. PubMed ID: 17472358 [TBL] [Abstract][Full Text] [Related]
8. ZRBA1, a Mixed EGFR/DNA Targeting Molecule, Potentiates Radiation Response Through Delayed DNA Damage Repair Process in a Triple Negative Breast Cancer Model. Heravi M; Kumala S; Rachid Z; Jean-Claude BJ; Radzioch D; Muanza TM Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):399-406. PubMed ID: 25823448 [TBL] [Abstract][Full Text] [Related]
9. Differential responses of EGFR-/AGT-expressing cells to the "combi-triazene" SMA41. Matheson SL; McNamee JP; Jean-Claude BJ Cancer Chemother Pharmacol; 2003 Jan; 51(1):11-20. PubMed ID: 12497201 [TBL] [Abstract][Full Text] [Related]
10. Synthesis of a prodrug designed to release multiple inhibitors of the epidermal growth factor receptor tyrosine kinase and an alkylating agent: a novel tumor targeting concept. Banerjee R; Rachid Z; McNamee J; Jean-Claude BJ J Med Chem; 2003 Dec; 46(25):5546-51. PubMed ID: 14640561 [TBL] [Abstract][Full Text] [Related]
11. The combi-targeting concept: mechanism of action of the pleiotropic combi-molecule RB24 and discovery of a novel cell signaling-based combination principle. Banerjee R; Huang Y; Qiu Q; McNamee JP; Belinsky G; Jean-Claude BJ Cell Signal; 2011 Apr; 23(4):630-40. PubMed ID: 21138763 [TBL] [Abstract][Full Text] [Related]
12. Synthesis of half-mustard combi-molecules with fluorescence properties: correlation with EGFR status. Rachid Z; Brahimi F; Domarkas J; Jean-Claude BJ Bioorg Med Chem Lett; 2005 Feb; 15(4):1135-8. PubMed ID: 15686928 [TBL] [Abstract][Full Text] [Related]
13. Multiple mechanisms of action of ZR2002 in human breast cancer cells: a novel combi-molecule designed to block signaling mediated by the ERB family of oncogenes and to damage genomic DNA. Brahimi F; Rachid Z; Qiu Q; McNamee JP; Li YJ; Tari AM; Jean-Claude BJ Int J Cancer; 2004 Nov; 112(3):484-91. PubMed ID: 15382076 [TBL] [Abstract][Full Text] [Related]
14. Subcellular distribution of a fluorescence-labeled combi-molecule designed to block epidermal growth factor receptor tyrosine kinase and damage DNA with a green fluorescent species. Todorova MI; Larroque AL; Dauphin-Pierre S; Fang YQ; Jean-Claude BJ Mol Cancer Ther; 2010 Apr; 9(4):869-82. PubMed ID: 20354119 [TBL] [Abstract][Full Text] [Related]
15. A bioanalytical investigation on the exquisitely strong in vitro potency of the EGFR-DNA targeting type II combi-molecule ZR2003 and its mitigated in vivo antitumour activity. Golabi N; Brahimi F; Huang Y; Rachid Z; Qiu Q; Larroque-Lombard AL; Jean-Claude BJ J Pharm Biomed Anal; 2011 Nov; 56(3):592-9. PubMed ID: 21764236 [TBL] [Abstract][Full Text] [Related]
16. Synthesis and studies on three-compartment flavone-containing combi-molecules designed to target EGFR, DNA, and MEK. Larroque-Lombard AL; Todorova M; Qiyu Q; Jean-Claude B Chem Biol Drug Des; 2011 May; 77(5):309-18. PubMed ID: 21294849 [TBL] [Abstract][Full Text] [Related]
18. Blockage of epidermal growth factor receptor by quinazoline tyrosine kinase inhibitors suppresses growth of human hepatocellular carcinoma. Liu Y; Poon RT; Shao W; Sun X; Chen H; Kok TW; Fan ST Cancer Lett; 2007 Apr; 248(1):32-40. PubMed ID: 16837130 [TBL] [Abstract][Full Text] [Related]
20. The combi-targeting concept: in vitro and in vivo fragmentation of a stable combi-nitrosourea engineered to interact with the epidermal growth factor receptor while remaining DNA reactive. Qiu Q; Domarkas J; Banerjee R; Merayo N; Brahimi F; McNamee JP; Gibbs BF; Jean-Claude BJ Clin Cancer Res; 2007 Jan; 13(1):331-40. PubMed ID: 17200372 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]